FOLD Amicus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FOLD

Price (delayed)

$11.21

Market cap

$3.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.82

Enterprise value

$3.47B

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics ...

Highlights
The EPS has grown by 11% from the previous quarter and by 11% YoY
The net income rose by 10% QoQ and by 6% YoY
Amicus Therapeutics's quick ratio has decreased by 29% YoY but it has increased by 4.9% from the previous quarter
The equity has plunged by 60% YoY and by 7% from the previous quarter
FOLD's debt is up by 2.7% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.amicusrx.com
Peers: BIIB BMRN ESPR LXRX

Key stats

What are the main financial stats of FOLD
Market
Shares outstanding
282.71M
Market cap
$3.17B
Enterprise value
$3.47B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
25.6
Price to sales (P/S)
9.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.55
Earnings
Revenue
$329.23M
EBIT
-$204.92M
EBITDA
-$199.58M
Free cash flow
-$166.93M
Per share
EPS
-$0.82
Free cash flow per share
-$0.58
Book value per share
$0.44
Revenue per share
$1.14
TBVPS
$1.82
Balance sheet
Total assets
$724.17M
Total liabilities
$601.12M
Debt
$452.12M
Equity
$123.05M
Working capital
$284.8M
Liquidity
Debt to equity
3.67
Current ratio
3.05
Quick ratio
2.59
Net debt/EBITDA
-1.52
Margins
EBITDA margin
-60.6%
Gross margin
88.3%
Net margin
-71.9%
Operating margin
-64.1%
Efficiency
Return on assets
-30.4%
Return on equity
-141.7%
Return on invested capital
-31.2%
Return on capital employed
-35%
Return on sales
-62.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FOLD stock price

How has the Amicus Therapeutics stock price performed over time
Intraday
1.45%
1 week
-3.45%
1 month
-14.03%
1 year
21.72%
YTD
-8.19%
QTD
-8.19%

Financial performance

How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$329.23M
Gross profit
$290.63M
Operating income
-$211.04M
Net income
-$236.57M
Gross margin
88.3%
Net margin
-71.9%
The operating margin rose by 14% QoQ
FOLD's net margin is up by 12% year-on-year and by 12% since the previous quarter
Amicus Therapeutics's operating income has increased by 12% QoQ but it has decreased by 6% YoY
The net income rose by 10% QoQ and by 6% YoY

Growth

What is Amicus Therapeutics's growth rate over time

Valuation

What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
25.6
P/S
9.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.55
The EPS has grown by 11% from the previous quarter and by 11% YoY
The P/B is 140% above the 5-year quarterly average of 10.5 and 29% above the last 4 quarters average of 19.6
The equity has plunged by 60% YoY and by 7% from the previous quarter
FOLD's price to sales (P/S) is 47% lower than its 5-year quarterly average of 18.4
FOLD's revenue is up by 8% year-on-year

Efficiency

How efficient is Amicus Therapeutics business performance
Amicus Therapeutics's return on equity has shrunk by 63% YoY and by 14% QoQ
The ROIC has contracted by 10% YoY but it has grown by 3.7% from the previous quarter
The ROS has grown by 9% YoY and by 8% from the previous quarter
FOLD's ROA is up by 5% from the previous quarter but it is down by 4.8% YoY

Dividends

What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FOLD.

Financial health

How did Amicus Therapeutics financials performed over time
FOLD's total assets is 20% greater than its total liabilities
Amicus Therapeutics's quick ratio has decreased by 29% YoY but it has increased by 4.9% from the previous quarter
FOLD's current ratio is down by 25% year-on-year but it is up by 10% since the previous quarter
FOLD's debt to equity has soared by 157% YoY and by 8% from the previous quarter
The equity has plunged by 60% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.